Clinical Trials
28 trialsA Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease
University of Nebraska
Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma
University of California, Davis
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse
University of California, Davis
Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme
European Organisation for Research and Treatment of Cancer - EORTC
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
Duke University
Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms
FDA Office of Orphan Products Development
SAPPHIRE
Isarna Therapeutics GmbH
Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma
Duke University
Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme
Duke University
Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas
National Cancer Institute (NCI)
Carmustine in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm
National Cancer Institute (NCI)
Internal Radiation Therapy Plus Carmustine Implants in Treating Patients With Recurrent or Refractory Malignant Glioma
National Cancer Institute (NCI)
Carmustine Implants in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma
National Cancer Institute (NCI)
Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma
Duke University
Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma
Duke University
Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer
Barbara Ann Karmanos Cancer Institute
Chemotherapy in Treating Patients With Recurrent Malignant Glioma
Duke University
Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain
Duke University
Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas
Duke University
Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer
National Cancer Institute (NCI)
The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme
INSYS Therapeutics Inc
Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Case Comprehensive Cancer Center
Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM
Methodist Healthcare - Memphis
Carmustine in Treating Patients With Recurrent Malignant Glioma
National Cancer Institute (NCI)
O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant Glioma
National Cancer Institute (NCI)